AORT - Artivion, Inc. Stock Price, Fair Value and News

23.46USD-0.04 (-0.17%)Delayed

Market Summary

USD23.46-0.04

Delayed

-0.17%

AORT Alerts

Big jump in Earnings (Y/Y)

AORT Stock Price

View Fullscreen

AORT RSI Chart

AORT Valuation

Market Cap

979.1M

Price/Earnings (Trailing)

-101.72

Price/Sales (Trailing)

2.66

EV/EBITDA

24.63

Price/Free Cashflow

91.65

AORT Price/Sales (Trailing)

AORT Profitability

EBT Margin

0.03%

Return on Equity

-3.26%

Return on Assets

-1.23%

Free Cashflow Yield

1.09%

AORT Fundamentals

AORT Revenue

Revenue (TTM)

368.2M

Rev. Growth (Yr)

17.06%

Rev. Growth (Qtr)

4.02%

AORT Earnings

Earnings (TTM)

-9.6M

Earnings Growth (Yr)

155.67%

Earnings Growth (Qtr)

289.51%

Breaking Down AORT Revenue

Last 7 days

-0.3%

Last 30 days

17.7%

Last 90 days

24.7%

Trailing 12 Months

57.2%

How does AORT drawdown profile look like?

AORT Financial Health

Current Ratio

6.04

Debt/Equity

1.06

Debt/Cashflow

0.06

AORT Investor Care

Shares Dilution (1Y)

2.10%

Diluted EPS (TTM)

-0.24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	368.2M	0	0	0
2023	319.8M	328.7M	339.7M	354.0M
2022	305.0M	309.2M	313.8M	313.8M
2021	257.9M	280.3M	287.3M	298.8M
2020	275.1M	257.8M	255.0M	253.2M
2019	268.4M	271.0M	274.3M	276.2M
2018	206.6M	227.3M	247.9M	262.8M
2017	182.4M	183.2M	181.9M	189.7M
2016	155.1M	166.6M	175.2M	180.4M
2015	142.7M	143.6M	143.2M	145.9M
2014	141.0M	142.1M	142.9M	144.6M
2013	135.0M	135.3M	138.1M	140.8M
2012	121.7M	125.5M	129.3M	131.7M
2011	117.1M	117.2M	118.5M	119.6M
2010	0	113.3M	115.0M	116.6M
2009	0	0	0	111.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Artivion, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 20, 2024	stanton marshall s.	sold	-44,511	20.39	-2,183	svp, clinical & md affair
Mar 15, 2024	green andrew m	sold	-29,240	20.00	-1,462	vp regulatory
Mar 14, 2024	green andrew m	sold	-79,880	20.00	-3,994	vp regulatory
Mar 12, 2024	getz matthew a	sold	-99,719	19.9439	-5,000	vp, human resources
Mar 05, 2024	stanton marshall s.	sold	-28,195	18.7221	-1,506	svp, clinical & md affair
Mar 05, 2024	davis john e	sold	-37,856	18.7222	-2,022	chief commercial officer
Mar 05, 2024	holloway jean f	sold	-44,558	18.7222	-2,380	svp, general counsel
Mar 05, 2024	green andrew m	sold	-21,717	18.7221	-1,160	vp regulatory
Mar 05, 2024	maney rochelle l.	sold	-21,661	18.7224	-1,157	vp, quality

Which funds bought or sold AORT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	reduced	-8.42	26,943	348,569	-%
May 16, 2024	JANE STREET GROUP, LLC	sold off	-100	-265,214	-	-%
May 16, 2024	Tidal Investments LLC	new	-	256,671	256,671	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-5.55	82,865	786,729	-%
May 15, 2024	AQR CAPITAL MANAGEMENT LLC	added	16.87	159,019	574,050	-%
May 15, 2024	Voya Investment Management LLC	reduced	-19.6	-14,159	278,000	-%
May 15, 2024	Royal Bank of Canada	reduced	-53.79	-142,000	171,000	-%
May 15, 2024	HSBC HOLDINGS PLC	added	12.28	110,167	443,142	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-3.53	976,225	7,869,110	-%
May 15, 2024	KENNEDY CAPITAL MANAGEMENT LLC	reduced	-75.56	-7,103,550	2,890,820	0.06%

Are Funds Buying or Selling AORT?

Are funds buying AORT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AORT

No. of Funds

AORT Alerts

Big jump in Earnings (Y/Y)

Unveiling Artivion, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	perceptive advisors llc	5.8%	2,383,978	SC 13G
Feb 14, 2024	macquarie group ltd	7%	2,873,431	SC 13G/A
Feb 13, 2024	vanguard group inc	6.41%	2,630,873	SC 13G/A
Feb 12, 2024	morgan stanley	5.8%	2,375,713	SC 13G/A
Feb 08, 2024	wellington management group llp	5.99%	2,459,646	SC 13G/A
Jan 22, 2024	blackrock inc.	16.7%	6,844,308	SC 13G/A
Feb 14, 2023	macquarie group ltd	6.60%	2,662,637	SC 13G/A
Feb 10, 2023	wasatch advisors inc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	6.97%	2,809,140	SC 13G/A
Feb 08, 2023	morgan stanley	5.4%	2,189,557	SC 13G

Recent SEC filings of Artivion, Inc.

View All Filings

Date Filed	Form Type	Document
May 17, 2024	8-K	Current Report
May 16, 2024	8-K	Current Report
May 13, 2024	4	Insider Trading
May 10, 2024	144	Notice of Insider Sale Intent
May 10, 2024	4	Insider Trading
May 09, 2024	144	Notice of Insider Sale Intent
May 07, 2024	10-Q	Quarterly Report
May 06, 2024	8-K	Current Report
Apr 01, 2024	ARS	ARS
Apr 01, 2024	DEF 14A	DEF 14A

Peers (Alternatives to Artivion, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.13%	32.26%	-0.09	0.28	5.77%	8.23%

Artivion, Inc. News

Latest updates

Artivion, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	4.0%	97.00	94.00	88.00	89.00	83.00	79.00	77.00	80.00	77.00	79.00	72.00	76.00	71.00	68.00	65.00	54.00	66.00	70.00	68.00	71.00	68.00
Gross Profit	3.0%	63.00	61.00	56.00	58.00	54.00	51.00	49.00	52.00	51.00	51.00	48.00	51.00	48.00	45.00	43.00	36.00	44.00	47.00	45.00	47.00	44.00
Operating Expenses	-35.0%	38.00	58.00	58.00	65.00	58.00	47.00	53.00	48.00	49.00	61.00	49.00	49.00	46.00	43.00	39.00	38.00	45.00	43.00	41.00	40.00	42.00
S&GA Expenses	-39.0%	31.00	50.00	51.00	57.00	50.00	38.00	41.00	39.00	39.00	51.00	39.00	41.00	39.00	36.00	34.00	32.00	39.00	38.00	34.00	35.00	37.00
R&D Expenses	-9.1%	7.00	8.00	6.00	7.00	7.00	8.00	12.00	9.00	10.00	9.00	10.00	8.00	8.00	7.00	6.00	6.00	6.00	5.00	6.00	6.00	6.00
EBITDA Margin	80.9%	0.14*	0.08*	0.09*	0.07*	0.07*	0.08*	0.02*	0.08*	0.09*	0.09*	0.15*	0.10*	-	-	-	-	-	-	-	-	-
Interest Expenses	25.3%	8.00	6.00	7.00	6.00	6.00	5.00	5.00	4.00	4.00	4.00	4.00	-	-	-	-	-	-	-	-	-	-
Income Taxes	55.1%	5.00	3.00	0.00	1.00	5.00	1.00	1.00	1.00	1.00	4.00	-2.64	0.00	-1.36	3.00	-1.31	-1.08	-1.47	2.00	-0.86	-0.09	-1.35
Earnings Before Taxes	2262.6%	13.00	-0.59	-9.42	-2.66	-8.92	3.00	-12.53	-3.30	-2.43	-16.09	8.00	-2.18	-4.50	-0.09	-4.18	-4.77	-8.13	2.00	-0.99	3.00	-1.65
EBT Margin	100.5%	0.00*	-0.06*	-0.05*	-0.06*	-0.07*	-0.05*	-0.11*	-0.04*	-0.04*	-0.05*	0.00*	-0.04*	-	-	-	-	-	-	-	-	-
Net Income	289.5%	8.00	-3.97	-9.80	-3.38	-13.53	2.00	-13.71	-4.26	-3.39	-20.10	11.00	-2.18	-3.14	-3.46	-2.87	-3.69	-6.66	-0.68	-0.13	3.00	-0.30
Net Income Margin	69.8%	-0.03*	-0.09*	-0.07*	-0.09*	-0.09*	-0.06*	-0.13*	-0.06*	-0.05*	-0.05*	0.01*	-0.04*	-	-	-	-	-	-	-	-	-
Free Cashflow	-202.2%	-9.10	9.00	6.00	5.00	-8.39	-2.31	1.00	-10.13	-2.84	-1.85	-6.18	-3.10	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-1.1%	784	792	775	778	757	763	743	765	782	793	819	810	795	789	782	693	621	606	593	597	587
Current Assets	-1.4%	277	281	267	264	241	247	238	240	245	248	257	238	236	235	234	287	214	187	181	189	179
Cash Equivalents	-13.3%	51.00	59.00	53.00	49.00	31.00	39.00	38.00	40.00	51.00	55.00	65.00	51.00	57.00	62.00	65.00	126	64.00	34.00	37.00	40.00	41.00
Inventory	-0.3%	82.00	82.00	79.00	78.00	76.00	74.00	73.00	74.00	76.00	77.00	78.00	76.00	73.00	73.00	69.00	63.00	54.00	53.00	48.00	45.00	44.00
Net PPE	-1.5%	38.00	38.00	37.00	38.00	39.00	39.00	36.00	36.00	37.00	38.00	37.00	36.00	31.00	33.00	32.00	32.00	32.00	32.00	30.00	31.00	30.00
Goodwill	-0.9%	245	247	243	246	246	244	235	241	248	250	252	255	254	260	254	186	184	187	183	188	187
Liabilities	-4.2%	489	511	503	495	477	478	488	483	484	492	507	509	498	461	456	397	344	320	315	315	314
Current Liabilities	-20.8%	46.00	58.00	55.00	56.00	44.00	50.00	46.00	42.00	43.00	45.00	61.00	59.00	58.00	60.00	54.00	49.00	44.00	45.00	42.00	37.00	36.00
Long Term Debt	2.4%	313	306	306	306	306	306	307	307	307	307	308	308	310	290	290	289	244	215	215	215	215
LT Debt, Current	-81.4%	0.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
LT Debt, Non Current	-100.0%	-	306	306	306	306	306	307	307	307	307	308	308	310	290	290	289	244	215	215	215	215
Shareholder's Equity	4.7%	295	282	272	283	280	284	255	282	297	301	312	302	297	329	326	297	277	286	278	282	273
Retained Earnings	15.7%	-40.37	-47.91	-43.93	-34.13	-30.75	-17.22	-19.39	-5.67	-1.41	2.00	22.00	11.00	14.00	20.00	23.00	26.00	30.00	37.00	37.00	38.00	35.00
Additional Paid-In Capital	2.0%	363	356	351	347	343	337	334	330	327	323	309	305	301	316	316	293	274	272	269	266	262
Accumulated Depreciation	-	-	-	-	-	-	-	-	-	-	-	-	-	-	78.00	-	-	-	71.00	-	-	-
Shares Outstanding	1.3%	41.00	41.00	43.00	42.00	42.00	40.00	40.00	40.00	40.00	39.00	39.00	39.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	666	-	-	-	725	-	-	-	1,070	-	-	-	694	-	-	-	1,078	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-150.7%	-5,493	10,838	7,232	6,909	-6,154	-217	3,976	-8,314	-598	716	-2,909	2,647	-3,039	5,450	7,679	-3,395	2,635	1,060	12,860	746	1,161
Share Based Compensation	-12.1%	3,478	3,956	3,187	3,938	3,341	3,155	3,089	2,934	3,166	3,240	2,876	2,115	2,480	-520	2,358	2,510	2,564	2,218	2,462	2,269	1,850
Cashflow From Investing	-35.3%	-3,611	-2,669	-2,068	7,078	-2,843	-2,668	-3,053	-2,286	-2,708	-2,812	15,516	-6,234	-810	-2,346	-66,301	-1,578	-2,903	-3,190	-17,107	-2,219	-1,427
Cashflow From Financing	145.2%	737	-1,630	-909	2,233	1,171	-859	252	-797	-235	-8,801	315	-1,642	-2,095	-1,682	-896	67,671	28,515	-657	-12.00	391	-1,215

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AORT Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 97,431	$ 83,229
Cost of products and preservation services:
Total cost of products and preservation services	34,485	29,502
Gross margin	62,946	53,727
Operating expenses:
General, administrative, and marketing	30,689	50,365
Research and development	6,946	7,223
Total operating expenses	37,635	57,588
Operating income (loss)	25,311	(3,861)
Interest expense	7,826	6,096
Interest income	(374)	(75)
Loss on extinguishment of debt	3,669	0
Other expense (income), net	1,409	(963)
Income (loss) before income taxes	12,781	(8,919)
Income tax expense	5,248	4,613
Net income (loss)	$ 7,533	$ (13,532)
Income (loss) per share:
Basic (in usd per share)	$ 0.18	$ (0.33)
Diluted (in usd per share)	$ 0.18	$ (0.33)
Weighted-average common shares outstanding:
Basic (in shares)	41,290	40,432
Diluted (in shares)	47,886	40,432
Net income (loss)	$ 7,533	$ (13,532)
Other comprehensive (loss) income:
Foreign currency translation adjustments	(3,137)	4,621
Unrealized gain (loss) from foreign currency intra-entity loans, net of tax	1,609	(1,005)
Comprehensive income (loss)	6,005	(9,916)
Products
Revenues:
Total revenues	71,114	62,291
Cost of products and preservation services:
Total cost of products and preservation services	23,750	19,533
Preservation services
Revenues:
Total revenues	26,317	20,938
Cost of products and preservation services:
Total cost of products and preservation services	$ 10,735	$ 9,969

AORT Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 51,118	$ 58,940
Trade receivables, net	74,301	71,796
Other receivables	2,272	2,342
Inventories, net	81,716	81,976
Deferred preservation costs, net	50,151	49,804
Prepaid expenses and other	17,227	15,810
Total current assets	276,785	280,668
Goodwill	245,030	247,337
Acquired technology, net	138,474	142,593
Operating lease right-of-use assets, net	42,492	43,822
Property and equipment, net	37,788	38,358
Other intangibles, net	29,506	29,638
Deferred income taxes	668	1,087
Other long-term assets	13,264	8,894
Total assets	784,007	792,397
Current liabilities:
Accounts payable	10,378	13,318
Accrued compensation	10,843	18,715
Accrued expenses	15,926	12,732
Taxes payable	2,090	3,840
Current maturities of operating leases	3,214	3,395
Accrued procurement fees	1,418	1,439
Current portion of long-term debt	270	1,451
Other current liabilities	1,691	2,972
Total current liabilities	45,830	57,862
Long-term debt	313,004	305,531
Contingent consideration	46,420	63,890
Non-current maturities of operating leases	42,861	43,977
Deferred income taxes	22,343	21,851
Deferred compensation liability	7,445	6,760
Non-current finance lease obligation	3,268	3,405
Other long-term liabilities	7,851	7,341
Total liabilities	489,022	510,617
Commitments and contingencies
Shareholders’ equity:
Preferred stock	0	0
Common stock (75,000 shares authorized, 43,224 and 42,569 shares issued in 2024 and 2023, respectively)	432	426
Additional paid-in capital	363,113	355,919
Retained deficit	(40,374)	(47,907)
Accumulated other comprehensive loss	(13,538)	(12,010)
Treasury stock, at cost, 1,487 shares as of March 31, 2024 ‎and December 31, 2023	(14,648)	(14,648)
Total shareholders’ equity	294,985	281,780
Total liabilities and shareholders’ equity	$ 784,007	$ 792,397

About Artivion, Inc.

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent and graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.

CEO	Mr. James Patrick Mackin
WEBSITE	https://artivion.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	1300

Artivion, Inc. Frequently Asked Questions

What is the ticker symbol for Artivion, Inc.? What does AORT stand for in stocks?

AORT is the stock ticker symbol of Artivion, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Artivion, Inc. (AORT)?

As of Fri May 17 2024, market cap of Artivion, Inc. is 979.09 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AORT stock?

You can check AORT's fair value in chart for subscribers.

What is the fair value of AORT stock?

You can check AORT's fair value in chart for subscribers. The fair value of Artivion, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Artivion, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AORT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Artivion, Inc. a good stock to buy?

The fair value guage provides a quick view whether AORT is over valued or under valued. Whether Artivion, Inc. is cheap or expensive depends on the assumptions which impact Artivion, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AORT.

What is Artivion, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, AORT's PE ratio (Price to Earnings) is -101.72 and Price to Sales (PS) ratio is 2.66. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AORT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Artivion, Inc.'s stock?

In the past 10 years, Artivion, Inc. has provided 0.108 (multiply by 100 for percentage) rate of return.